

Production, Quality Control and Biodistribution Assessment of ^{166}Ho -BPAMD as a New Bone Seeking Agent

Authors : H. Yousefnia, N. Amraee, M. Hosntalab, S. Zolghadri, A. Bahrami-Samani

Abstract : The aim of this study was the preparation of a new agent for bone marrow ablation in patients with multiple myeloma. ^{166}Ho was produced at Tehran research reactor via $^{165}\text{Ho}(n,\gamma)^{166}\text{Ho}$ reaction. Complexion of Ho-166 with BPAMD was carried out by the addition of about 200 μg of BPAMD in absolute water to 1 mci of $^{166}\text{HoCl}_3$ and warming up the mixture 90 $^{\circ}\text{C}$ for 1 h. ^{166}Ho -BPAMD was prepared successfully with radio chemical purity of 95% which was measured by ITLC method. The final solution was injected to wild-type mice and bio distribution was determined up to 48 h. SPECT images were acquired after 2 and 48 h post injection. Both the bio distribution studies and SPECT imaging indicated high bone uptake, while accumulation in other organs was approximately negligible. The results show that ^{166}Ho -BPAMD has suitable characteristics and can be used as a new bone marrow ablative agent.

Keywords : bone marrow ablation, BPAMD, ^{166}Ho , SPECT

Conference Title : ICRR 2015 : International Conference on Radiopharmacy and Radiopharmaceuticals

Conference Location : Madrid, Spain

Conference Dates : March 26-27, 2015